Known targets — ChEMBL curated mechanism
BCL2BCL2A1BCL2L1BCL2L10BCL2L2MCL1
The experimentally established mechanism targets of Obatoclax. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 known ✓ | Q07817 | 2/20 | 0.41 |
| ▸ | BCL2 known ✓ | P10415 | 1/20 | 0.41 |
| ▸ | MCL1 known ✓ | Q07820 | 1/20 | 0.41 |
| ▸ | BCL2A1 known ✓ | Q16548 | 1/20 | 0.41 |
| ▸ | BCL2L2 known ✓ | Q92843 | 1/20 | 0.41 |
| ▸ | BCL2L10 known ✓ | Q9HD36 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.41 |
| ▸ | ASPH | Q12797 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | BAD | Q92934 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Obatoclax SCHEMBL29519876 | 1.00 | RAB9A (0.41) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL29354696 | 1.00 | RAB9A (0.41) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL2751250 | 1.00 | RAB9A (0.41) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL631676 | 1.00 | RAB9A (0.41) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL681264 | 0.93 | BCL2L1 (0.47) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL29358370 | 0.93 | BCL2L1 (0.47) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL15201882 | 0.93 | BCL2L1 (0.47) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL681265 | 0.93 | BCL2L1 (0.47) | RAB9AMAPTNPC1KDM4ECASP3 | |
| SCHEMBL630995 | 0.89 | AURKA (0.37) | RAB9AMAPTNPC1KDM4ECASP3 | |
| SCHEMBL630994 | 0.89 | AURKA (0.37) | RAB9AMAPTNPC1KDM4ECASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268985-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | IMMUNE SYSTEM KEY LTD. (IL) | 2025-08-28 | — | — | US | claimed |
| WO-2023199313-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | IMMUNE SYSTEM KEY LTD. (IL) | 2023-10-19 | — | — | WO | claimed |
| EP-1644363-B1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC (CA) | 2012-02-22 | — | — | EP | claimed |
| EP-3429570-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES | ORYZON GENOMICS SA (ES) | 2026-05-20 | — | — | EP | disclosed |
| EP-4688805-A1 | CYCLIC D-PEPTIDES, DERIVATIVES, COMPOSITIONS AND USES THEREOF | Immune System Key Ltd. (IL) | 2026-02-11 | — | — | EP | disclosed |
| EP-4684836-A2 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | Oryzon Genomics, S.A. (ES) | 2026-01-28 | — | — | EP | disclosed |
| EP-3429571-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | ORYZON GENOMICS SA (ES) | 2025-10-08 | — | — | EP | disclosed |
| US-20250268985-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | IMMUNE SYSTEM KEY LTD. (IL) | 2025-08-28 | — | — | US | disclosed |
| EP-4507709-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | Immune System Key Ltd. (IL) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024228200-A1 | CYCLIC D-PEPTIDES, DERIVATIVES, COMPOSITIONS AND USES THEREOF | IMMUNE SYSTEM KEY LTD. (IL) | 2024-11-07 | — | — | WO | disclosed |
| WO-2023199313-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | IMMUNE SYSTEM KEY LTD. (IL) | 2023-10-19 | — | — | WO | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | THE JACKSON LABORATORY (US) | 2013-07-18 | — | — | US | disclosed |
| EP-1644363-B1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC (CA) | 2012-02-22 | — | — | EP | disclosed |
| US-7709477-B2 | Methods for treating cancer | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| US-20090098118-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | ROCHE GLYCART AG (CH) | 2009-04-16 | — | — | US | disclosed |
| US-20080318903-A1 | METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| US-20060035945-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | INVESTISSEMENT QUEBEC (CA) | 2006-02-16 | — | — | US | disclosed |
| WO-2005117908-A2 | TRIHETEROCYCLIC COMPOUNDS COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES | GEMIN X BIOTECHNOLOGIES, INC. (CA) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267073-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | INVESTISSEMENT QUEBEC (CA) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318903-A1 | METHODS FOR TREATING CANCER | HCCS, EIF2AK2, ZC3HAV1 | BCL2L1 662/4885BCL2 129/4885MCL1 60/4885 |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | BCL2L1 40/4885BCL2 300/4885MCL1 13/4885 |
| US-20050267073-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | ZC3HAV1, HCCS, HAVCR2 | BCL2L1 723/4885BCL2 201/4885MCL1 58/4885 |
| US-20250268985-A1 | BCL2 INHIBITOR AND PEPTIDE COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES | BCL2, BCL2L13, BCL2L1 | BCL2L1 3/4885BCL2 1/4885MCL1 14/4885 |
| US-20130184342-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | BAK1, SSB, MRE11 | BCL2L1 57/4885BCL2 23/4885MCL1 5/4885 |
| US-20090098118-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | BCL2L1 7/4885BCL2 2/4885MCL1 13/4885 |
| US-20060035945-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | ZC3HAV1, HCCS, HAVCR2 | BCL2L1 723/4885BCL2 201/4885MCL1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.